Steroid-unresponsive asthma

Seminars in Respiratory and Critical Care Medicine

Volumn 23, Issue 4, 2002, Pages 387-398

  Leung, Donaid Y M ^a   Spahn, Joseph D ^a   Szefler, Stanley J ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Asthma; Steroid resistant asthmaglucocorticoid; T cells

Indexed keywords

ALLERGEN; CORTICOSTEROID; CYTOKINE; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR BETA; HYDROCORTISONE; INTERLEUKIN 2; INTERLEUKIN 4; THEOPHYLLINE; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ASTHMA; CORTICOSTEROID THERAPY; CUSHING SYNDROME; CYTOKINE PRODUCTION; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNE RESPONSE; INFLAMMATION; NEUTROPHILIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOCIAL PSYCHOLOGY; T LYMPHOCYTE; TREATMENT FAILURE;

EID: 0036687883     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34353     Document Type: Review

References (70)

1. Corticosteroid action and resistance in asthma
2. Steroid resistance in bronchial asthma
3. Corticosteroid resistance in chronic asthma
4. Glucocorticoid resistance in chronic asthma: Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro
5. High-dose systemic glucocorticoid therapy in the treatment of severe asthma: A case of resistance and patterns of response
6. Glucocorticoid resistance in chronic asthma: Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A
7. Steroid-resistant asthma: Immunologic and pharmacologic features
8. Dysregulation of interleukin-4, interleukin-5, and interferon gamma gene expression in steroid-resistant asthma
9. Molecular mechanisms of glucocorticoid action
10. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
11. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma
12. Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction
13. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor
14. Syndromes of glucocorticoid resistance
15. Steroid-resistant asthma: Cellular mechanisms contributing to inadequate response to glucocorticoid therapy
16. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids
17. A novel action of IL-13: Induction of diminished monocyte glucocorticoid receptor-binding affinity
18. Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma
19. The R576 IL-4 receptor alpha allele correlates with asthma severity
20. Leung DYM Association of asthmatic steroid insensitivity with an I1-4 gene promoter polymorphism
21. Do African-Americans display a diminished response to glucocorticoids (GCs)?
22. Difficult-to-control asthma: Clinical characteristics of steroid-insensitive asthma
23. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases
24. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma
25. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes
26. Glucocorticoid receptor beta: View I
27. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans
28. The human glucocorticoid receptor beta isoform: Expression, biochemical properties, and putative function
29. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action
30. Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor
31. High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids
32. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta
33. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma
34. Absence of glucocorticoid receptor-beta in mice
35. In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation
36. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics
37. Increased T cell receptor vbeta8+ T cells in bronchoalveolar lavage fluid of subjects with poorly controlled asthma: A potential role for microbial superantigens
38. Superantigens and their potential role in human disease
39. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens
40. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocortioids
41. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night
42. Glucocorticoid receptor-beta is associated with reduced steroid responsiveness at night in nocturnal asthma
43. Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma
44. Steroid-resistant asthma: New insights and implications for management
45. Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis
46. The frequency and severity of cat allergy vs. dog allergy in atopic children
47. Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: Schools as a major site of exposure
48. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma
49. A link between chronic asthma and chronic infection
50. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma
51. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
52. Leukotriene antagonist prevents exacerbation of asthma during reduction of highose inhaled corticosteroid
53. Addition of leukotriene antagonists to therapy in chronic persistent asthma: A randomised double-blind placebo-controlled trial
54. Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma
55. Circadian variations in theophylline concentrations and the treatment of nocturnal asthma
56. Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma
57. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI
58. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics
59. Treatment of severe steroid dependent preschool asthma with nebulized budesonide suspension
60. Monitoring glucocorticoid therapy: A pharmacokinetic approach
61. Coexistence of glucocorticoid receptor and pharmacokinetic abnormalities: Factors that contribute to a poor response to treatment with glucocorticoids in children with asthma
62. Osteoporosis in the corticosteroid-treated patient with asthma
63. Management of severe asthma
64. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin
65. Cyclosporin A treatment and airways inflammation in corticosteroid -dependent asthma
66. Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients
67. Role of airway remodeling in severe asthma
68. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
69. Molecular and cellular mechanisms of allergic disease
70. Clinical outcomes of steroid insensitive asthma